Recursion Pharmaceuticals has reported updated data from its ELUCIDATE & TUPELO trials, but the stock has failed to mount a ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

In December 2025, J.P. Morgan upgraded Recursion Pharmaceuticals after REC-4881 showed rapid, durable polyp burden reductions and a favorable safety profile in familial adenomatous polyposis patients, ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best NASDAQ stocks under $10 to buy. As of December 15, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has a ‘Hold’ or equivalent rating from ...

Wondering if Recursion Pharmaceuticals at around $4.83 is a beaten down bargain or a value trap? This breakdown walks through what the current market price is really implying. The stock has bounced ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – Rallybio Corporation (Nasdaq: RLYB), a ...

Abstract: A fundamental scalability restriction of most Inductive Logic Programming (ILP) systems is that they search syntactically defined program spaces and cannot utilize relations in data. While ...